Result of General Meeting
Biodexa Pharmaceuticals announced the approval of four resolutions at its General Meeting, including a share reorganization that reduces the number of ordinary shares by a factor of 10,000 without changing proportional ownership. The ADS ratio will change from 500,000:1 to 50:1 effective July 30, 2026, with approximately 51.5 million ordinary shares and 1.03 million ADSs outstanding post-reorganization.
Key figures
- Ads ratio new
- 50:1
- Ads ratio old
- 500,000:1
- Ads outstanding
- 1029063
- Ordinary shares post reorg
- 51453281
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.